Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 306
Westmead, New South Wales, Australia
- Arcutis Clinical Site 303
East Melbourne, Victoria, Australia
- Arcutis Clinical Site 207
Surrey, British Columbia, Canada
- Arcutis Clinical Site 205
Ajax, Ontario, Canada
- Arcutis Clinical Site 218
Barrie, Ontario, Canada
- Arcutis Clinical Site 103
London, Ontario, Canada
- Arcutis Clinical Site 133
Mississauga, Ontario, Canada
- Arcutis Clinical Site 165
Oakville, Ontario, Canada
- Arcutis Clinical Site 109
Peterborough, Ontario, Canada
- Arcutis Clinical Site 241
Richmond Hill, Ontario, Canada
- Arcutis Clinical Site 106
Waterloo, Ontario, Canada
- Arcutis Clinical Site 242
Montreal, Canada
- Arcutis Clinical Site 239
Beverly Hills, California, United States
- Arcutis Clinical Site 225
Encino, California, United States
- Arcutis Clinical Site 112
Fremont, California, United States
- Arcutis Clinical Site 120
Irvine, California, United States
- Arcutis Clinical Site 208
Santa Monica, California, United States
- Arcutis Clinical Site 174
Aventura, Florida, United States
- Arcutis Clinical Site 167
Coral Gables, Florida, United States
- Arcutis Clinical Site 104
Sanford, Florida, United States
- Arcutis Clinical Site 214
Indianapolis, Indiana, United States
- Arcutis Clinical Site 217
Louisville, Kentucky, United States
- Arcutis Clinical Site 213
Metairie, Louisiana, United States
- Arcutis Clinical Site 125
Rockville, Maryland, United States
- Arcutis Clinical Site 212
Detroit, Michigan, United States
- Arcutis Clinical Site 216
New Brighton, Minnesota, United States
- Arcutis Clinical Site 171
New York, New York, United States
- Arcutis Clinical Site 115
High Point, North Carolina, United States
- Arcutis Clinical Site 173
Portland, Oregon, United States
- Arcutis Clinical Site 135
Pittsburgh, Pennsylvania, United States
- Arcutis Clinical Site 162
Austin, Texas, United States
- Arcutis Clinical Site 104
College Station, Texas, United States
- Arcutis Clinical Site 164
Houston, Texas, United States
- Arcutis Clinical Site 163
Pflugerville, Texas, United States
- Arcutis Clinical Site 110
San Antonio, Texas, United States
- Arcutis Clinical Site 161
San Antonio, Texas, United States
- Arcutis Clinical Site 169
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Apr 2020
- Primary completion
- 24 Feb 2021
- Completion
- 24 Feb 2021
- Last update posted
- 5 Apr 2024
- Registered enrollment
- 230
- Registry id
- NCT04378569
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.